TSXV:ARCH (Canada)  
Arch Biopartners Inc logo

Arch Biopartners Inc

C$ 3.00 (+0.67%) Sep 30
P/E:
At Loss
P/B:
0
Market Cap:
C$ 186.99M ($ 136.29M)
Enterprise V:
C$ 190.79M ($ 139.06M)
Volume:
11.88K
Avg Vol (2M):
8.69K
Also Trade In:
Volume:
11.88K
Market Cap C$:
186.99M
Market Cap $:
136.29M
PE Ratio:
At Loss
Avg Vol (2-Month):
8.69K
Enterprise Value C$:
190.79M
Enterprise Value $:
139.06M
PB Ratio:
0
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. Its under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.
Name Current Vs Industry Vs History
Cash-To-Debt 0.13
Equity-to-Asset -2.15
Debt-to-Equity -1.1
Debt-to-EBITDA 141.55
Interest Coverage 0.1
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -7104.69
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 39.33
9-Day RSI 32.86
14-Day RSI 33.7
6-1 Month Momentum % -19.51
12-1 Month Momentum % 91.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.75
Quick Ratio 0.75
Cash Ratio 0.24

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.9
Name Current Vs Industry Vs History
ROA % -13.3
ROIC % 2.47
ROC (Joel Greenblatt) % 6.4

GF Value Rank

Name Current Vs Industry Vs History
Price-to-Free-Cash-Flow 166.66
Price-to-Operating-Cash-Flow 166.66
EV-to-EBIT 6154.62
EV-to-EBITDA 6154.62
EV-to-FCF 172.38
Earnings Yield (Greenblatt) % 0.02

Financials

TSXV:ARCH's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$) 0
EPS (TTM) (C$) -0.004
Beta 0.39
Volatility % 105.1
14-Day RSI 33.7
14-Day ATR (C$) 0.077633
20-Day SMA (C$) 3.1395
12-1 Month Momentum % 91.86
52-Week Range (C$) 1.69 - 5.3
Shares Outstanding (Mil) 62.33

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Arch Biopartners Inc Filings

Document Form Filing Date
No Filing Data

Arch Biopartners Inc Analysis

Share your research